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ABSTRACT
Objective. The aim of this study was to evaluate the
introduction of diagnostic laparoscopy (DLS) in patients
with colorectal peritoneal metastases (PM) to prevent non-
therapeutic laparotomies during cytoreductive surgery with
hyperthermic intraperitoneal chemotherapy
(CRS ? HIPEC).
Methods. Patients with histologically proven colorectal
PM who underwent a laparotomy for potential CRS ?
HIPEC from January 2006 to January 2019 were retro-
spectively identified from a prospectively maintained
database. In 2012, DLS was introduced in the preoperative
work-up for CRS ? HIPEC in our academic center. The
rates of non-therapeutic laparotomies, major postoperative
complications (Clavien–Dindo grade III or higher), and
survival outcomes were investigated for patients who
underwent a laparotomy before (cohort A) and after (cohort
B) the introduction of DLS. In cohort B, the reasons to
refrain from DLS were retrospectively explored from
medical records.
Results. Overall, 172 patients were included [cohort A: 48
patients (27.9%); cohort B: 124 patients (72.1%)]. A
significant drop in the rate of non-therapeutic laparotomies
occurred in cohort B compared with cohort A (21.0 vs.
35.4%: p = 0.044), despite only 85 patients (68.5%) from
cohort B undergoing DLS in our academic center. The
most important reason to refrain from DLS was a recently
performed DLS or laparotomy in the referring hospital
(48.7%). Major postoperative complications, in-hospital
mortality, and survival outcomes were similar for both
cohorts.
Conclusions. Performing DLS during the preoperative
work-up for CRS ? HIPEC prevents non-therapeutic
laparotomies in patients with colorectal PM. We recom-
mend performing this laparoscopic screening in an
experienced HIPEC center.
Worldwide, carefully selected patients with limited and
resectable colorectal peritoneal metastases (PM) are treated
with cytoreductive surgery (CRS) followed by hyperther-
mic intraperitoneal chemotherapy (HIPEC) with the aim of
achieving long-term survival.1–5 Patients with low tumor
burden, as expressed by the peritoneal cancer index (PCI),
and in whom a complete cytoreduction of all macroscopic
visible colorectal PM can be achieved (CC-0), benefit the
most from this extensive surgical procedure in terms of
survival.5–9 Therefore, CRS ? HIPEC for patients with
colorectal PM is restricted to those with a PCI B 20, in
whom a complete macroscopic cytoreduction can be
reached.8–11
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To date, surgical oncologists are still discovering the
real extent and potential resectability of colorectal PM at
the time of operative exploration, as current imaging
modalities underestimate both important prognostic fac-
tors.12–14 Unfortunately, 20–40% of these patients are
excluded for CRS ? HIPEC directly after exploratory
laparotomy, resulting in an open–close procedure (e.g. non-
therapeutic laparotomy).15,16 For patients, this is a very
undesirable postoperative outcome as it is not only asso-
ciated with a significant risk of postoperative complications
and a diminished quality of life (QoL) in the short term,
but it also delays enrollment into other therapies. From a
healthcare perspective, an aborted CRS ? HIPEC proce-
dure is expensive and leads to a longer wait list.
Suggestions have been made to use diagnostic laparo-
scopy (DLS) in the preoperative work-up for
CRS ? HIPEC to prevent non-therapeutic laparotomies
during CRS in patients with colorectal PM.17,18 Several
studies show that DLS is an accurate and safe staging tool
in patients with peritoneal disease.16,18–23 However, the
limitations of these studies are the variety of primary
tumors that are included and the highly selected way a DLS
is used. Since 2012, HIPEC surgeons from our academic
center have introduced DLS as part of the preoperative
work-up for CRS ? HIPEC to prevent unnecessary
laparotomies. This provides the opportunity to compare a
historical cohort of patients with colorectal PM who were
scheduled for CRS ? HIPEC before the introduction of
DLS with those with colorectal PM who were scheduled
for CRS ? HIPEC after DLS was part of the preoperative
work-up. Our aim was to evaluate the implementation of
DLS in the preoperative work-up for CRS ? HIPEC, and
the impact on preventing non-therapeutic laparotomies in
this vulnerable population.
METHODS
Design, Setting, and Patients
All consecutive patients with histologically proven
colorectal PM who underwent an exploratory laparotomy
for potential CRS ? HIPEC from January 2006 to January
2019 were retrospectively identified from a prospectively
maintained institutional database. Patients were divided
into two different cohorts according to their operation date
to evaluate the implementation and impact of performing
DLS during the preoperative work-up for CRS ? HIPEC
to prevent non-therapeutic laparotomies. Study cohort A
consisted of a historical group of patients with colorectal
PM who underwent an exploratory laparotomy for potential
CRS ? HIPEC before the introduction of DLS in the
preoperative work-up for CRS ? HIPEC (January 2006 to
December 2011), while study cohort B consisted of
patients with colorectal PM who underwent an exploratory
laparotomy for potential CRS ? HIPEC after the intro-
duction of DLS in the preoperative work-up for
CRS ? HIPEC (January 2012 to January 2019). The Ethics
Committee of the University Medical Center Groningen
approved this study (METc 201800395).
Primary and Secondary Outcomes
The primary outcome was the rate of non-therapeutic
laparotomies during CRS for cohorts A and B. Secondary
outcomes were major postoperative complications, in-
hospital mortality, disease-free survival (DFS), and overall
survival (OS). Furthermore, to evaluate the implementation
of DLS in the preoperative work-up, we calculated the
number of patients who did not undergo DLS in our aca-
demic center after the introduction of DLS in the
preoperative work-up for CRS ? HIPEC (e.g. cohort B).
Reasons for refraining from DLS were retrospectively
explored from digital medical records.
Major postoperative complications are defined as grade
3 or higher according to the Clavien–Dindo classification
system, and registered up to 90 days after surgery.24 These
types of complications require endoscopic, radiologic, or
surgical interventions, or admission to the intensive care
unit. Postoperative mortality is defined as death within
30 days after surgery; OS is defined as the time between
the initial exploratory laparotomy and death or date of last
follow-up in censored cases; and DFS was defined as the
time between CRS ? HIPEC and the date of first recur-
rence or last follow-up in censored cases.
Preoperative Evaluation and Staging
All referred patients with colorectal PM underwent a
standardized preoperative evaluation to investigate the
extent and resectability of the peritoneal disease and to rule
out other distant metastases. All patients were staged with a
computed tomography (CT) of the thorax, abdomen, and
pelvis. Since 2012, laparoscopic evaluation in our aca-
demic center has been part of the preoperative work-up for
CRS ? HIPEC to further assess the extent of colorectal
PM and the possibility of performing a complete cytore-
duction. Patients with an absolute contraindication for
CRS ? HIPEC on imaging (i.e. extra-abdominal metas-
tases or more than three liver metastases) were directly
referred to a medical oncologist and did not undergo DLS.
These patients are not represented in this article as they
were not scheduled for CRS ? HIPEC.
Every laparoscopic evaluation was performed under
general anesthesia and a pneumoperitoneum was estab-
lished by using an optical trocar. In all cases, a 30
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laparoscope was used and introduced through an umbilical
port. One or two additional trocars were placed under
direct vision according to the surgeon’s discretion. All 13
abdominopelvic regions of the peritoneal cavity were sys-
tematically reviewed and adhesiolysis was only performed
when deemed necessary. The laparoscopic PCI was cal-
culated and the possibility to perform a complete
cytoreduction during an exploratory laparotomy was esti-
mated. The visibility of each abdominopelvic region, the
laparoscopic PCI, and the possibility to achieve a complete
cytoreduction were all recorded in the operation report.
Cytology samples and biopsies were only taken as indi-
cated. During several expert sessions with our four HIPEC
surgeons, we created a 4-point scale for the degree of
visibility of the abdominal cavity during DLS (i.e. grade I:
visibility of two or less abdominopelvic regions; grade II:
visibility of three to eight abdominopelvic regions; grade
III: visibility of at least the diaphragm regions, pelvis
region, and small bowel regions; and grade IV: visibility of
all 13 abdominopelvic regions).
Hereafter, during a weekly multidisciplinary meeting,
eligibility for CRS ? HIPEC was determined by an
experienced team consisting of medical oncologists, gas-
troenterologists, radiologists, and oncologic surgeons. In
general, patients with colorectal PM were considered eli-
gible for CRS ? HIPEC when they met the following
criteria: (1) PCI B 20; (2) resectable primary tumor; (3)
absence of extra-abdominal metastases; (4) absence of
massive peritoneal disease involvement of the small bowel
or its mesentery; (5) Eastern Cooperative Oncology Group
(ECOG) performance status B 3; and (6) American Society
of Anesthesiologists (ASA) score of \ 3. Up to three
resectable liver metastases were not considered a con-
traindication for CRS ? HIPEC.
Cytoreductive Surgery with Hyperthermic
Intraperitoneal Chemotherapy
CRS ? HIPEC was performed according to the Dutch
protocol.3 In summary, CRS was performed only in
patients with completely resectable colorectal PM, and
HIPEC was performed only after reaching a complete or
nearly complete cytoreduction.
Each procedure started with an exploratory laparotomy
to calculate the PCI score and judge the resectability of the
colorectal PM. The procedure was terminated in cases
where the patient was deemed not suitable for CRS ?
HIPEC, and palliative surgery was performed only
according to the surgeon’s discretion (e.g. non-therapeutic
laparotomy). Patients with resectable colorectal PM
underwent CRS with the aim of removing all visible tumor
tissue. The resection status after CRS was judged with the
completeness of cytoreduction (CC) score.25 CC-0
indicates no visible or palpable residual tumor tissue in the
peritoneal cavity; CC-1 indicates residual tumor deposits
\ 2.5 mm; CC-2 indicates residual tumor deposits
between 2.5 mm and 2.5 cm; and CC-3 indicates residual
tumor deposits [ 2.5 cm, or confluence of unre-
sectable tumor deposits at any site within the abdomen or
pelvis.
HIPEC was performed in the case of a complete (CC-0)
or nearly complete (CC-1) cytoreduction, whereby the
abdominal cavity was perfused with mitomycin C (35 mg/
m2) according to the open ‘Coliseum’ technique, with a
temperature of 40–41 C for 90 min.26 After HIPEC,
reconstruction surgery, including bowel anastomoses, and,
if deemed necessary, a colostomy, was performed. All
patients were admitted to the intensive care unit for at least
1 postoperative day until cardiac and pulmonary functions
were normal.
Follow-Up
Clinical follow-up occurred within 1 month after sur-
gery and thereafter on a quarterly basis for a minimum of
5 years. In the case of suspected recurrence based on
clinical symptoms or an increase in carcinoembryonic
antigen (CEA) level, a CT of the thorax and abdomen was
performed.
Data Collection
Relevant data were prospectively collected in an insti-
tutional database and consisted of patient characteristics,
tumor characteristics, extent of peritoneal disease, previous
treatments, operative characteristics, postoperative mor-
tality and morbidity, and short- and long-term survival
outcomes.
Reasons to refrain from DLS after its introduction in
2012 were retrospectively explored from digital medical
records.
Statistical Analyses
All statistical analyses were conducted using SPSS
Statistics version 24.0 (IBM Corporation, Armonk, NY,
USA). Categorical variables are reported as number (n) and
percentages (%) and were analyzed using the Chi square
test or Fisher’s exact test. Continuous variables are repor-
ted as median [interquartile range (IQR)] or
mean ± standard deviation (SD) and were analyzed using
the Student’s t test or Mann–Whitney U test. Kaplan–Meier
survival analyses were performed to describe DFS and OS
for study cohorts A and B. All tests were performed two-
sided, and a p value\ 0.05 was considered statistically
significant.
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RESULTS
Baseline Characteristics
One hundred and seventy-two patients with histologi-
cally proven colorectal PM underwent an exploratory
laparotomy for potential CRS ? HIPEC in our academic
center between January 2006 and January 2019. Forty-
eight patients (27.9%) underwent an exploratory laparo-
tomy before the introduction of DLS in the preoperative
work-up for CRS ? HIPEC (i.e. cohort A), and 124
patients (72.1%) underwent an exploratory laparotomy
after the introduction of DLS in the preoperative work-up
for CRS ? HIPEC (i.e. cohort B). Table 1 shows a com-
parison of patient and tumor characteristics between
cohorts A and B. Patients from cohort B, on average,
were older (62 vs. 55 years; p\ 0.002) and had a higher
body mass index (BMI; 26.6 vs. 23.4 kg/m2; p\ 0.001).
Furthermore, these patients were less frequently diagnosed
with an N2 (41.1 vs. 45.8%; p = 0.024) or M1 status (50.0
vs. 77.1%; p = 0.004) and were less frequently treated with
adjuvant chemotherapy (25 vs. 41.7%; p = 0.001). On the
other hand, patients from cohort B were more frequently
diagnosed with metachronous onset of colorectal PM (54.0
vs. 33.3%; p = 0.015). Other baseline characteristics were
similar between the cohorts.
Non-therapeutic Laparotomies
Table 2 presents the surgical characteristics of the
exploratory laparotomy and postoperative morbidity rates
for cohorts A and B.
None of the patients from cohort A underwent DLS
during the preoperative work-up for CRS ? HIPEC as it
was not common clinical practice between 2006 and 2011.
An unexpectedly low number of patients (85, 68.5%)
underwent DLS in our academic center after the intro-
duction of DLS in the preoperative work-up for
CRS ? HIPEC The number of non-therapeutic laparo-
tomies for the entire cohort was 43 (25.0%). A non-
therapeutic laparotomy occurred less frequently in cohort B
when compared with historical cohort A (21.0 vs. 35.4%;
p = 0.044). Causes for the occurrence of a non-therapeutic
laparotomy did not differ between both cohorts
(p = 0.496).
As the number of patients who underwent DLS in cohort
B was unexpectedly low, additional analyses were per-
formed to identify the direct effect of DLS on the
prevention of non-therapeutic laparotomies. In this specific
case, patients were no longer divided by their operation
date (e.g. cohort A or B), but by whether they underwent
DLS (n = 89) or not (n = 83). Non-therapeutic laparo-
tomies occurred less frequently in patients who underwent
DLS compared with patients who did not undergo DLS
(18.0 vs. 32.5%; p = 0.028).
Reasons to Refrain from Diagnostic Laparoscopy
An overview of the reasons to refrain from DLS for
patients in cohort B after the introduction of the preoper-
ative work-up for CRS ? HIPEC is presented in Table 3.
Refraining from DLS in our academic center was most
frequently caused by the fact that the patient recently
underwent a laparotomy (30.8%) or DLS (17.9%) in the
referring hospital, or a laparotomy in our own academic
center (17.9%). For these patients, in the decision-making
process additional DLS in our academic center after recent
abdominal surgery was not considered useful. Furthermore,
DLS was not performed in seven patients (17.9%) who
showed a clear response to neoadjuvant chemotherapy on
CT imaging. In six patients (15.4%), reasons to refrain
from DLS could not be identified from the digital medical
records.
Interestingly, in patients who did not undergo DLS after
its introduction in the preoperative work-up for CRS ?
HIPEC, a non-therapeutic laparotomy occurred in 11
patients (28.2%). The specific reason for refraining from
DLS was not predictive of an occurrence of a non-thera-
peutic laparotomy (p = 0.437) [data not shown]. There
seemed to be a trend toward an increase in non-therapeutic
laparotomies in patients from cohort B who did not
undergo DLS compared with patients from the same cohort
who underwent DLS in the preoperative work-up (28.2 vs.
17.6%), but this trend did not reach significance
(p = 0.107).
Laparoscopic Evaluation
Table 4 presents the surgical characteristics of the DLS
and postoperative morbidity rates of the 85 patients
(68.5%) from cohort B who underwent DLS prior to
exploratory laparotomy. Good laparoscopic evaluation of
the abdominal cavity (i.e. grade 3 or 4) was possible in 64
patients (74.1%). The conversion rate during DLS
amounted to 21.2%, and no reoperations occurred. The
postoperative complication rate was low (3.5%) and con-
sisted only of Clavien–Dindo grade II complications (e.g.
urinary tract infection and bacteremia). In patients who
underwent DLS in the preoperative work-up for CRS ?
HIPEC, only 15 non-therapeutic laparotomies (17.6%)
occurred.
Surgical Morbidity and Mortality
Table 2 presents the surgical characteristics of the
exploratory laparotomy, along with the postoperative
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TABLE 1 Baseline
characteristics from all patients
with colorectal PM who
underwent an exploratory
laparotomy for potential
CRS ? HIPEC, stratified by the
operation date (cohort A:
between 2006 and 2011; cohort
B: between 2012 and 2019)
Cohort A (n = 48) Cohort B (n = 124) p value
Patient characteristics
Age, years (mean ± SD) 55.0 ± 9.7 62 ± 9.9 0.002
Female sex 22 (45.8) 60 (48.4) 0.764
BMI, kg/m2 (mean ± SD) 23.4 ± 4.7 26.6 ± 4.7 \ 0.001
ASA 0.871
1 6 (12.5) 19 (15.3)
2 37 (77.1) 91 (73.4)
3 5 (10.4) 14 (11.3)
Comorbidity
Diabetes mellitus 4 (8.3) 11 (8.9) 0.379
Hypertension 7 (14.6) 26 (21.0) 0.256
Cardiac comorbidity 7 (14.6) 12 (9.7) 0.878
Lung comorbidity 7 (14.6) 13 (10.5) 0.206
Tumor characteristics
Primary tumor location 0.455
Right colon 23 (47.9) 41 (33.1)
Transverse colon 2 (4.2) 10 (8.1)
Left colon 4 (8.3) 15 (12.1)
Sigmoid 13 (27.1) 40 (32.3)
Rectum 6 (12.5) 18 (14.5)
Signet cell histology 4 (8.3) 12 (9.7) 0.759
T-stage primary tumor 0.087
B 3 18 (37.5) 56 (45.2)
4 25 (52.1) 66 (53.2)
N status primary tumor 0.024
0 7 (14.6) 35 (28.2)
1 14 (29.2) 36 (29.0)
2 22 (45.8) 51 (41.1)
M status primary tumor
0 9 (18.8) 57 (46.0) 0.004
1 37 (77.1) 62 (50.0)
Onset of colorectal PM
Synchronous 32 (66.7) 57 (46.0) 0.015
Metachronous 16 (33.3) 67 (54.0)
Synchronous liver metastases 4 (8.3) 12 (9.7) 0.785
Prior CRC treatments
Prior CRC surgery 42 (87.5) 112 (90.3) 0.588
Prior chemotherapy 14 (29.2) 48 (38.7) 0.360
Neoadjuvant chemotherapy 4 (8.4) 24 (19.4) 0.568
Adjuvant chemotherapy 20 (41.7) 31 (25.0) 0.001
Bold values are statistically significant (p\ 0.05)
Data are expressed as n (%) unless otherwise specified
PM peritoneal metastases, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy,
SD standard deviation, BMI body mass index, ASA American Society of Anesthesiologists, synchronous
onset PM diagnosed at the time of presentation with colorectal cancer, metachronous onset PM diagnosed
after initial curative colorectal resection, CRC colorectal cancer, prior chemotherapy chemotherapy used in
the past, neoadjuvant chemotherapy chemotherapy prior to CRS with HIPEC, adjuvant chemotherapy
chemotherapy after CRS with HIPEC
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morbidity rates for cohorts A and B. One hundred and
twenty-nine patients (75.0%) underwent CRS ? HIPEC
during an exploratory laparotomy. Treatment
characteristics, consisting of the number of anatomic
resections, PCI score, operating time, blood loss, and
resection status, were similar for both cohorts.
TABLE 2 Treatment
characteristics from all patients
with colorectal PM who
underwent an exploratory
laparotomy for potential
CRS ? HIPEC, stratified by the
operation date (cohort A:
between 2006 and 2011; cohort
B: between 2012 and 2019)
Cohort A (n = 48) Cohort B (n = 124) p value
DLS routinely performed, yes 0 (0.0) 85 (68.5) \ 0.001
HIPEC type 0.044
Open CRS ? HIPEC 31 (64.6) 98 (79.0)
Open–close procedure 17 (35.4) 26 (21.0)
Main reason for the open–close procedure 0.496
PCI[ 20 8 (47.1)a 13 (50.0)
Too much small bowel involvementb 4 (23.5) 4 (15.4)
Irresectable primary tumorc 2 (11.8) 7 (26.9)
Irresectable liver metastases 3 (17.6) 2 (7.7)
PCI at HIPEC 0.121
0–5 4 (36.4) 34 (28.8)
6–10 2 (18.2) 26 (22.0)
11–15 0 (0.0) 20 (16.9)
16–20 0 (0.0) 16 (15.0)
21–25 3 (27.3) 13 (11.0)
[ 25 2 (18.2) 9 (7.6)
Total anatomic resections [median (IQR)] 4 (1–6) 4 (2–7) 0.410
Anastomoses 0.161
0 31 (64.6) 57 (46.0)
1 12 (25.0) 44 (35.5)
C 2 5 (10.5) 23 (18.5)
Stoma post HIPEC 21 (43.8) 63 (50.8) 0.406
Operation time, min [median (IQR)] 493 (364–614) 471 (352–538) 0.217
Blood loss, mL [median (IQR)] 700 (475–1325) 750 (500–1500) 0.790
Resection status 0.126
CC-0 or CC-1 31 (64.6) 98 (79.0)
C CC-2 17 (35.4) 26 (21.0)
Length of hospital stay, days [median (IQR)] 15 (10–21) 16 (12–24) 0.239
Reoperation 4 (8.3) 15 (12.1) 0.480
In hospital mortality 1 (2.1) 2 (1.6) 0.833
Complication rate, Clavien–Dindo grade 0.424
I 4 (8.3) 10 (8.1)
II 14 (29.2) 40 (32.3)
III 7 (14.6) 23 (18.5)
IV 7 (14.6) 6 (4.8)
Bold values are statistically significant (p\ 0.05)
Data are expressed as n (%) unless otherwise specified
PM peritoneal metastases, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy,
DLS diagnostic laparoscopy, PCI peritoneal cancer index, IQR interquartile range, CC completeness of
cytoreduction
aDuring study period A (2006–2011), the PCI classification system was not used systematically in The
Netherlands. In five patients from Cohort A with an open–close procedure, we concluded that the PCI
would most likely have been above 20 based on the information from the operation report (i.e. extensive
disease involvement of all nine abdominal regions)
bMassive peritoneal disease involvement of the small bowel or its mesentery, whereby removal will very
likely lead to short bowel syndrome
cTumor intertwined with vital structures, making safe removal impossible
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Major postoperative complications after exploratory
laparotomy occurred in 14 patients (29.2%) from cohort A
and 29 patients (23.4%) from cohort B (p = 0.424). Rela-
parotomy was necessary in 4 (8.3%) and 15 patients
(12.1%), respectively (p = 0.480). Overall in-hospital
mortality was 1.7% and did not differ between the cohorts
(p = 0.833).
Survival Outcomes
The mean OS for the entire group of patients was
30.1 months [95% confidence interval (CI)
26.0–34.2 months], and the mean OS was similar for
cohorts A and B [25.9 months (95% CI 19.5–32.3) vs.
29.5 months (95% CI 25.9–33.1 months); p = 0.132].
For additional analyses of OS and DFS after CRS ?
HIPEC, patients with a non-therapeutic laparotomy were
excluded (n = 43). The mean OS for patients after
CRS ? HIPEC was 36.4 months (95% CI
31.6–41.2 months), and the mean OS was similar for
cohorts A and B [34 months (95% CI 25.9–42.1 months)
vs. 34 months (95% CI 30.2–37.8 months); p = 0.523].
The mean DFS for the entire cohort of patients was
20.7 months (95% CI 16.1–25.2 months), and the mean
DFS was similar between cohorts A and B [20.9 months
(95% CI 13.2–28.7 months) vs. 18.5 months (95% CI
14.7–22.4 months); p = 0.706].
DISCUSSION
In this observational study, consisting of 172 consecu-
tive patients with colorectal PM, we demonstrated that non-
therapeutic laparotomies during CRS occurred less fre-
quently after the introduction of DLS as part of the
preoperative work-up for CRS ? HIPEC.
Proper selection of patients with colorectal PM for
CRS ? HIPEC is a known challenge as possible survival
gain is difficult to weigh against treatment-related mor-
bidity and mortality. From this perspective, for patients and
clinicians, the most disappointing outcome after this major
procedure is a non-therapeutic laparotomy as it is associ-
ated with an increased risk of postoperative morbidity and
a diminished QoL without providing any improvement in
survival. These days, up to 40% of patients with PM are
still confronted with a non-therapeutic laparotomy during
CRS.15,16 Previous research showed that DLS is an accu-
rate and safe staging tool in patients with PM and might
prevent non-therapeutic laparotomies in patients with
extensive disease.16,18–23 In this study, we showed that the
rate of non-therapeutic laparotomies significantly dropped
from 35.4 to 21.0% after the introduction of DLS in our
preoperative work-up, despite the fact that only 68.5% of
patients underwent DLS in our academic center after this
introduction. In the group of patients who underwent DLS,
a trend towards an ever-lower rate of non-therapeutic
laparotomies was found (17.6%). Additional analyses
showed that recent abdominal surgery in two of three
patients was the main reason to refrain from DLS in our
academic center, resulting in an unexpectedly higher rate
of non-therapeutic laparotomies (28.2%) in these patients.
An explanation for this phenomenon might be the fact that
surgeons from the referral centers in most cases were
unexpectedly confronted with colorectal PM during a pri-
mary tumor resection. At that moment, the focus would be
on referring the patient to a highly experienced HIPEC
center as quickly as possible, and therefore less attention
might be paid to the true extent of the peritoneal disease.
In our current study, some significant differences in
baseline characteristics were found between patients who
underwent an exploratory laparotomy for potential
CRS ? HIPEC before and after the introduction of DLS in
the preoperative work-up for CRS ? HIPEC (i.e. cohort A
and B, respectively). Patients from cohort B were, on
average, older and had a higher BMI, which can be
explained by the increase in the global average life
expectancy and the increase in obesity rates during the past
20 years. Both age and BMI are not considered a con-
traindication for CRS ? HIPEC in our academic center.
Patients from cohort B were also less frequently treated
with adjuvant chemotherapy. Due to a lack of scientific
evidence, there is no worldwide consensus about the use
TABLE 3 Reasons for not routinely performing DLS in patients
with colorectal PM from cohort B (n = 39)
Reasons for not routinely performing DLS
Recent laparotomy in another hospital (\ 4 weeks) 12 (30.8)
Recent DLS in another hospital (\ 4 weeks) 7 (17.9)
Recent laparotomy in our academic center (\ 4 weeks) 7 (17.9)
Clear response on neoadjuvant therapy on imaging 7 (17.9)
Unknown 6 (15.4)
Impact on open–close procedures
HIPEC type
Open CRS ? HIPEC 28 (71.8)
Open–close procedure 11 (28.2)
Main reason for the open–close procedure
PCI[ 20 5 (45.5)
Too much small bowel involvement 2 (18.2)
Irresectable primary tumor 3 (27.3)
Irresectable liver metastases 1 (9.1)
Data are expressed as n (%)
DLS diagnostic laparoscopy, PM peritoneal metastases, Cohort B
patients who underwent an exploratory laparotomy for potential
CRS ? HIPEC between January 2012 and January 2019, CRS
cytoreductive surgery, HIPEC hyperthermic intraperitoneal
chemotherapy, PCI peritoneal cancer index
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and timing of perioperative chemotherapy. Over the years,
we have become more careful in applying adjuvant
chemotherapy to patients after CRS ? HIPEC because of
the increase in morbidity and temporal decrease in QoL,
which are both associated with chemotherapy. It is very
unlikely that these differences in age, BMI, and the use of
adjuvant chemotherapy could explain the rate drop of non-
therapeutic laparotomies in cohort B. Furthermore, patients
from cohort B were also more frequently diagnosed with
metachronous onset of colorectal PM. The most likely
explanation for this phenomenon seems the shift towards
an increased awareness about CRS ? HIPEC among sur-
geons from regional hospitals. In the past, patients with
metachronous colorectal PM in particular were frequently
referred to a medical oncologist for palliative treatment
options instead of an experienced HIPEC center. These
days, patients are referred to our academic center in a low-
threshold way, resulting in the treatment of more patients
with metachronous onset of colorectal PM. To the best of
our knowledge, there are no scientific publications
TABLE 4 Visibility and
postoperative morbidity of DLS
in patients with colorectal PM
from cohort B (n = 85)
Time intervals
Interval of colorectal PM to DLS, months [median (IQR)] 1 (0–2)
Interval of colorectal PM to HIPEC, months [median (IQR)] 2 (2–4)
Visibility during DLS
Grade of visibilitya
I (very poor) 11 (12.9)
II (poor) 8 (9.4)
III (good) 11 (12.9)
IV (excellent) 53 (62.4)







[ 25 4 (4.7)
Recovery after DLS
Length of hospital stay, days [median (IQR)] 2 (2–3)
Reoperation 0 (0.0)






Urinary tract infection 2 (2.4)
Bacteremia with unknown cause 1 (1.2)
Impact on open–close procedures
HIPEC type
Open CRS ? HIPEC 70 (82.4)
Open–close procedure 15 (17.6)
Data are expressed as n (%) unless otherwise specified
DLS diagnostic laparoscopy, PM peritoneal metastases, Cohort B patients who underwent an exploratory
laparotomy for potential CRS ? HIPEC between January 2012 and January 2019, IQR interquartile range,
PCI peritoneal cancer index, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal
chemotherapy
aGrade I: visibility of two or less abdominopelvic regions; grade II: visibility of three to eight abdomi-
nopelvic regions; grade III: visibility of at least the diaphragm regions, pelvis region, and small bowel
regions; grade IV visibility of all 13 abdominopelvic regions
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regarding the impact of the onset of colorectal PM on the
rate of non-therapeutic laparotomies during
CRS ? HIPEC.
Overall, six other studies have reported data about the
impact of DLS on preventing non-therapeutic laparotomies
in patients with PM during CRS.16,19–23 It should be noted
that none of these studies focused only on patients with
colorectal PM; a variation of 3, up to 11, primary tumor
types were included per study. The overall rate of non-
therapeutic laparotomies during CRS in patients who
underwent DLS ranged from 12.5 to 37.0%. In most
studies, DLS was used in only highly selected
patients.19,21,22 When DLS was routinely performed in all
patients with PM, low rates of non-therapeutic laparo-
tomies during CRS were reported (ranging from 15.2 to
17.0%).20,23 In only three studies was it possible to com-
pare rates of non-therapeutic laparotomies between patients
who underwent DLS and patients who did not undergo
DLS prior to CRS.16,19,22 These studies all reported a sig-
nificant drop in the rate of non-therapeutic laparotomies in
patients who underwent DLS when compared with patients
who did not undergo DLS prior to CRS. However, it
remains challenging to compare the results from our pre-
sent study with the current literature because of differences
in patient populations, tumor types, and indications to
perform DLS.
In The Netherlands, HIPEC procedures are only per-
formed in highly experienced tertiary referral centers by a
dedicated team of surgeons. As previously mentioned, most
surgeons from referral centers have less experience in
reporting the extent of colorectal PM according to the PCI
score, and therefore might understage the extent of disease
and overestimate the possibility of achieving a complete
cytoreduction. With this obtained knowledge, we are pay-
ing more attention to early detection and referring of
patients with colorectal PM to our academic center.
Patients will undergo laparoscopic evaluation by one of our
HIPEC surgeons to investigate the extent and resectability
of the colorectal PM, independently of prior abdominal
surgery performed at the referral center. With these
adjustments, we suspect that the rate of non-therapeutic
laparotomies in patients with colorectal PM will drop even
further in our academic center in the following years.
In the near future, it is possible that DLS will play a
smaller role in patient selection because detection rates of
PM from current preoperative imaging modalities are
improving.27,28 In a recent study consisting of 49 patients
with colorectal PM, MRI PCI was strongly correlated with
the surgical PCI.28 Two radiologists with extensive expe-
rience in detecting colorectal PM could identify all patients
with resectable disease based on a PCI score below 21.
Larger series are still necessary to provide more evidence
of the accuracy of detection and staging of colorectal PM.
DLS in the preoperative work-up for CRS ? HIPEC will
not be easily curbed as other advantages remain, such as
taking biopsies to confirm the presence or absence of
peritoneal disease and provide additional information for
future systemic therapies.
This study has certain strengths and limitations. To the
best of our knowledge, this is the first study that specifi-
cally describes the impact of DLS to prevent non-
therapeutic laparotomies in a large cohort of patients with
colorectal PM. Another strength of the current study is the
presence of an adequate comparison group; an historical
cohort of all consecutive patients who underwent an
exploratory laparotomy for potential CRS ? HIPEC before
DLS was introduced in our academic center. Gathered
knowledge from this study provided crucial information
about our daily practice to further improve the imple-
mentation of DLS in the preoperative work-up for
CRS ? HIPEC. On the other hand, our study has some
limitations due to its retrospective design and single-center
approach. Selection bias might have occurred, although
most data were obtained from a prospectively maintained
institutional database, and reasons to refrain from DLS in a
subset of patients were further investigated. Although our
HIPEC surgeons are extensively trained to perform
CRS ? HIPEC procedures and already had extensive
experience in gastrointestinal surgery, study results may
have also been influenced by their learning curves in the
beginning of this study period. Learning curves from our
academic center and other Dutch hospitals have already
been published elsewhere.29
CONCLUSIONS
Non-therapeutic laparotomies during CRS (e.g. open–
close procedures) are prevented in patients with colorectal
PM when DLS is performed during the preoperative work-
up for this major abdominal procedure. We recommend
that only HIPEC surgeons perform this laparoscopic eval-
uation to ensure adequate staging of the extent of colorectal
PM and the possibility of achieving a complete
cytoreduction.
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